EU Panel Backs Frontline Daratumumab/VMP Combo for Multiple Myeloma

July 27, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of daratumumab in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The recommendation is based on the pivotal, open-label phase III ALCYONE study, in which daratumumab plus VMP demonstrated a … (leggi tutto)